findmyKOL

Monica Guma, MD

Enriched profile

Professor of Medicine and Chief of the Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego · University of California San Diego

ORCIDNPI
Region🇺🇸 La Jolla, CA · West · United StatesSpecialtyRheumatologyFocusRheumatoid Arthritis Research and Therapies+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2023–2024NIH funding2013–2026

Monica Guma is Professor of Medicine and Chief of the Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego at University of California San Diego. OpenAlex indexes 185 publications with 10,594 citations (h-index 47); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.

Data verified 17 Aug 2026

Overview

Updated 27 Aug 2026

Monica Guma, M.D., PH.D., is Professor of Medicine and Chief of the Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego at University of California San Diego. The public record shows 185 publications with 10,594 citations (h-index 47), centered on Rheumatoid Arthritis Research and Therapies, Immune Cell Function and Interaction, Metabolomics and Mass Spectrometry Studies. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 3 companies, 6 NIH-funded awards (2013–2026).

  • Most recent indexed publication: 2026 · The Journal of rheumatology
  • Top research focus: Rheumatoid Arthritis Research and Therapies
  • 4 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 3 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Rheumatoid Arthritis2 trialsOsteoarthritis1 trialLupus (SLE)1 trialST Elevation Myocardial Infarction1 trialGout

Research focus

OpenAlex concept fingerprint
Rheumatoid Arthritis Research and TherapiesImmune Cell Function and InteractionMetabolomics and Mass Spectrometry StudiesOsteoarthritis Treatment and MechanismsGout, Hyperuricemia, Uric Acid

Drugs & molecules

across trials, industry payments and publications
Bimzelxgeneric · BimekizumabClinical trialsIndustry payments1PublicationsTremfyageneric · GuselkumabClinical trialsIndustry payments1Publications

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trialsIndustry payments8University of California, San DiegoClinical trials3Industry paymentsJanssen Scientific Affairs, LLCClinical trialsIndustry payments2

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
185publications

Distinct works indexed by OpenAlex, matched via ORCID; 14 in PubMed.

10,594citations

Total citations across indexed works.

47h-index

Hirsch index (OpenAlex). i10-index 88.

Clinical & industry

trials, payments and federal funding
4clinical trials

Investigator role on registered studies.

View trials
3companies · 2023–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments
6NIH grants · 2013–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

3 companies reported payments to CMS in program years 2023–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    57.2%
    TNF inhibitor23.5%
    Enbrel Sureclick31%Humira(Cf) Pen20%Enbrel18%Humira18%Humira Pen14%
    Part D<11 patients
    Folate Analog Metabolic Inhibitor17.6%
    Methotrexate100%
    Part D14 patients
  • Antiparasitic

    20.2%
    Antimalarial20.2%
    Hydroxychloroquine Sulfate100%
    Part D11 patients
  • Metabolism & gastrointestinal

    10.9%
    Corticosteroid7.3%
    Prednisone100%
    Part D<11 patients
    Aminosalicylate3.5%
    Sulfasalazine100%
    Part D<11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)79.1% facility · 20.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

6 NIH research awards on record, funded 20132026 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Roxana Coras41Jessica Murillo‐Saich22Michael Karin19

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/monica-guma-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Other

    arthritis.org/liveyes/podcast/new-podcast/microbiome-gut-health-podcast

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →arthritis.org

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    Autonomous University of Barcelona, Spain

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatology.ucsd.edu
  • Ph.D. in Immunology

    Pompeu Fabra University, Barcelona, Spain

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →rheumatology.ucsd.edu

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Guest

    "Microbiome, Gut Health & Arthritis" podcast (Episode 60), Arthritis Foundation, discussing diet's impact on disease activity and therapeutic response, released January 19

    2021
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →arthritis.org

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.